HERGET, JAN, AND IVAN F. MCMURTRY. Dexamethasone potentiates hypoxic vasoconstriction in salt solution-perfused rat lungs. Am. J. Physiol. 253 (Heart Circ. Physiol. 22): H574-H581, 1387.-Isolated rat lungs perfused with blood or plasma develop good hypoxic pressor reactivity, but those flushed of blood and perfused solely with physiological salt solution (PSS) show decreased or no hypoxic vasoconstriction.
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Because the handling of rats during collection of blood increases the plasma corticosterone levels, we wondered whether the difference between blood and PSS perfusion was due partly to higher glucocorticoid activity with blood than with PSS. Treatment of lung donors with the synthetic glucocorticoid dexamethasone (2 mg/kg im 3 h before isolation) or addition of dexamethasone (4.2 x 10e6 M) to the perfusate increased markedly the hypoxic pressor reactivity of rat lungs perfused with PSS plus albumin (4 g/100 ml). In comparison, dexamethasone did not cause a significant increase in the already vigorous hypoxic pressor reactivity of blood-perfused lungs, but it reversed the blunted pressor reactivity of lungs perfused with blood collected from adrenalectomized rats. The potentiation of hypoxic vasoconstriction by dexamethasone required >40 min to develop and was inhibited by a loo-fold higher concentration of progesterone, a glucocorticoid receptor antagonist. Although dexamethasone and the cyclooxygenase blocker meclofenamate (3.1 x lo-" M) caused similar decreases in perfusate levels of cyclooxygenase metabolites, the glucocorticoid was much more effective in inducing hypoxic vasoconstriction in PSS-perfused lungs. Thus a reduction of cyclooxygenase metabolism might have contributed to, but did not fully account for, the glucocorticoid effect. Dexamethasone also caused small increases in base-line perfusion pressure and in pressor reactivity to angiotensin II. These results indicate that physiological glucocorticoid receptor stimulation increases the vasoreactivity of PSSperfused rat lungs and support the idea that the difference in hypoxic pressor reactivity between blood and PSS perfusion is due partly to a difference in glucocorticoid activity.
hypoxia; pulmonary circulation; vascular reactivity; glucocorticoid activity; arachidonic acid metabolism ISOLATED RAT LUNGS are often used to study the mechanism of hypoxic pulmonary vasoconstriction. They develop large hypoxic pressor responses when perfused with homologous blood or plasma, but show decreased or no hypoxic pressor reactivity when flushed of blood and perfused solely with physiological salt solutions (6, 24) . This difference suggests there are substances in plasma that augment or maintain the hypoxic vasoreactivity of isolated rat lungs. Although addition of certain excitatory agents, e.g., angiotensin II, 4aminopyridine, vanadate, and high [K'] , to the salt solution perfusate of rat lungs increases vascular reactivity and potentiates hypoxic pressor responses (6, 24) , there is no evidence that any of these agents is responsible for the vigorous pressor reactivity of blood-or plasma-perfused lungs (24). The following observations have prompted us to question whether the effect of blood or plasma might be due partly to glucocorticoid activity. First, although high pharmacological levels (>10s4 M) of glucocorticoids inhibit systemic vascular reactivity, lower concentrations (~10~' M) have been observed to increase vasoreactivity (2,3). Second, in the experiments with physiological salt solution, it is possible the flushing of blood from the rat lung removes endogenous corticosterone due to its relatively weak receptor binding (4). Third, the collection by cardiac puncture of homologous blood for perfusion of rat lungs involves stresses that can activate the hypothalamic-pituitary-adrenocortical system and increase the plasma concentration of corticosterone (30). For example, 5 s of handling can increase rat plasma corticosterone levels from 3 x 10m7 M to 8 x 1O-7 M (30). A ccordingly, it could be proposed that the difference between blood (or plasma) and salt solution in supporting the hypoxic pressor reactivity of isolated rat lungs is due partly to a higher level of glucocorticoid activity with blood than with salt solution. To test this idea we examined the effect of the synthetic glucocorticoid, dexamethasone, on hypoxic and angiotensin II pressor reactivity in rat lungs perfused with either physiological salt solution, blood from intact rats, or blood from adrenalectomized rats.
METHODS
The experimental preparation was the isolated rat lung (24, 25) . Lungs were removed from 260-to 400-g male Sprague-Dawley rats after injection of pentobarbital sodium (30-40 mg ip) and heparin (100 IU iv). They were suspended in a humid chamber and ventilated with a humid mixture of 95% air-5% CO, (normoxic gas) at 65 breaths/min and at an inspiratory pressure of 9 cmHzO and an end-expiratory pressure of 2.5 cmHZO. They were perfused through a pulmonary arterial cannula by peristaltic pump with either physiological salt solution or homologous blood (see below) at a constant flow of 0.04 ml. g body wt-' l min. Effluent perfusate drained from a left ventricular cannula into a reservoir and was sam-H574 V, Sigma) . In all experiments with PSS the first 20 ml through the lungs was discarded, leaving a recirculated volume of 30 ml. Homologous blood (15-25 ml) to be used as perfusate was collected in heparinized syringes by cardiac puncture of two or three adult male Sprague Dawley rats anesthetized with ether. Three different groups of blood donors were used: intact (normal) rats, rats anesthetized with ether and adrenalectomized bilaterally through retroperitoneal incisions 4-6 days before collection of blood, and rats anesthetized with ether and subjected to sham adrenalectomy. The adrenalectomized rats were offered 0.9% NaCl as drinking water. The first experiment examined the separate effects of in vitro and in vivo treatment with dexamethasone (dexamethasone sodium phosphate injection, Elkins-Sinn) on hypoxic and angiotensin II pressor reactivity in PSSperfused lungs. Three groups of lungs (n = 5) were studied: lungs from untreated rats (control), lungs from untreated rats perfused with 4.2 x IO-' M dexamethasone (8, 9, 14, 18) (dexamethasone added to PSS to a calculated concentration of 4.2 x lo-" M before lung perfused), and lungs from rats treated with dexamethasone (2 mg/kg dexamethasone im 3 h before lung isolation) (8). After 1 h (8, 9, 14, 18) of perfusion the lungs were prestimulated twice with arterial injections of 0.3 pg angiotensin II (Sigma) and 5 min of ventilation with 0% 02-5% COZ-95% N, to induce pressor reactivity (24, 25) . Dose-pressor responses to hypoxia and angiotensin II were then elicited by alternate challenges with bolus injections of 0.05, 0.1, 0.2, and 0.3 ,ug angiotensin II and 4-min periods of ventilation with 10, 5, 3, and 0% O,-5% Cop-balance N,.
The next experiment tested whether the prestimulation with angiotensin II (24) was necessary for the effect of in vitro dexamethasone on hypoxic pressor reactivity in PSS-perfused lungs. Two groups of lungs (n = 5) were studied: lungs from untreated rats (control) and lungs from untreated rats perfused with 4.2 x lo-" M dexamethasone. The perfusate of control lungs contained an equivalent volume of the dexamethasone vehicle (i.e., to 50 ml of PSS was added 0.025 ml of a solution containing 1 mg sodium sulfite, 19.4 mg sodium citrate, and 0.01 ml benzyl alcohol per ml of 0.9% NaCl). After 1 h of perfusion and two challenges with 5 min of 0% 02, a dose response to hypoxia was elicited by successive 4-min challenges with 15, 10,5, and 0% OZ-5% COa-balance N,. To test for interaction between dexamethasone and angiotensin II on hypoxic vasoconstriction, these lungs were challenged after the hypoxic dose-response curve with 0.1 ug angiotensin II and then 5 min later a pressor response to 5% O2 was again elicited.
The third experiment examined the effect of in vivo treatment with dexamethasone on hypoxic and angiotensin II pressor reactivity in blood-perfused lungs. Two groups of lungs (n = 5) perfused with blood from normal rats were studied: lungs from rats treated with dexamethasone (2 mg/kg dexamethasone im 3 h before lung isolation) and lungs from rats treated similarly with the vehicle for dexamethasone (control). After 20 min of equilibration and two challenges with 5 min of 3% 02, a dose response to hypoxia was elicited by successive 6-min challenges with 15, 10,5, and 0% 02-5% C02-balance N,. Ten minutes after the response to 0% 02, a dose response to angiotensin II was elicited by successive injections of 0.05, 0.1, 0.2, and 0.5 pug angiotensin II.
The fourth experiment addressed whether perfusion with blood from adrenalectomized rats would depress hypoxic and angiotensin II pressor reactivity and whether in vivo treatment of the lung donors with dexamethasone would counteract the depression. Three groups of lungs (n = 6) were studied: lungs isolated from rats treated with the vehicle for dexamethasone and perfused with blood from sham-adrenalectomized rats (control), lungs isolated from rats treated with vehicle and perfused with blood from adrenalectomized rats, and lungs isolated from rats treated with dexamethasone (2 mg/kg dexamethasone im 3 h before lung isolation) and perfused with blood from adrenalectomized rats. All lungs were first flushed with 20 ml of PSS before beginning perfusion with blood. After 20 min of equilibration the lungs were challenged initially with two 5-min periods of 3% 0, and then dose responses to hypoxia and angiotensin II were elicited as described in the third experiment. Lung weight was measured at end of perfusion and again after drying to constant weight for calculation of wet-to-dry weight ratio.
The fifth experiment tested whether a more physiological concentration (13) of dexamethasone in vitro would also potentiate hypoxic pressor reactivity in PSS-perfused lungs and whether the potentiation was prevented by the glucocorticoid receptor antagonist, progesterone (7, 16, 28) . Four groups of lungs (n = 4) were studied:
lungs perfused with PSS containing both the vehicle for dexamethasone and that for progesterone (0.1 ml dimethyl sulfoxide/50 ml perfusate, Sigma) (control), lungs perfused with PSS containing vehicle for dexamethasone and 5 x 10s5 M progesterone (U-3672, Upjohn), lungs perfused with 5 x 10B7 M dexamethasone and dimethyl sulfoxide, and lungs perfused with 5 x 10m5 M progesterone and 5 x 10B7 M dexamethasone. The latter lungs were exposed to progesterone for 10 min before dexamethasone was added to the perfusate. After 70 min of perfusion the lungs were prestimulated twice with 0.2 pug angiotensin II and once wit,h 5 min of 0% 02 to induce pressor reactivity (24, 25) . A dose response to hypoxia was then elicited by successive 4-min challenges with 15, 10, 5, and 0% OZ-5% COB-balance N,.
To further test the involvement of glucocorticoid receptor stimulation in the potentiating effect of dexamethasone, we monitored the time required for potentiation of hvpoxic vasoconstriction after addition of dexa-H576 GLUCOCORTICOID AND HYPOXIC VASOCONSTRICTION methasone to the perfusate. Two groups of PSS-perfused lungs isolated from normal rats were studied. After 20 min of equilibration and two 5min challenges with 3% 0, at lo-min intervals, the vehicle for dexamethasone was added to the control group (n = 5) and 4.2 X lo-" M dexamethasone was added to the other (n = 5). The lungs were then challenged repeatedly with 5 min of 3% 0, at lo-min intervals for an additional 100 min of perfusion.
The next series of experiments tested whether the effect of dexamethasone was due to inhibition of arachidonic acid (8, 9, (12) (13) (14) 18) or glucose (13,28) metabolism. We first compared the effect of combined in vivo and in vitro exposure with either dexamethasone or meclofenamate on hypoxic pressor reactivity in angiotensin II prestimulated lungs. Three groups of PSS-perfused lungs were studied: lungs isolated from rats treated with dexamethasone vehicle and perfused with PSS containing the vehicle (control), lungs isolated from rats treated with 2 mg/kg dexamethasone 3 h before lung isolation and perfused with 4.2 x 10s6 M dexamethasone, and lungs isolated from rats treated with 2 mg/kg sodium meclofenamate (Warner-Lambert) ip 3 h before isolation and perfused with 9.3 x lo-" M meclofenamate. After 20 min of equilibration and prestimulation with 0.2 pg angiotensin II and 5 min of 0% 02, a hypoxic dose response was elicited. Lung weight was measured at end of perfusion and again after drying to constant weight for calculation of wet-to-dry weight ratio. We next compared the effects of in vitro exposure with either dexamethasone or meclofenamate on hypoxic vasoconstriction, cyclooxygenase activity, and lactate and pyruvate production in PSS-perfused lungs t.hat were not prestimulated with angiotensin II. Three groups of lungs isolated from untreated rats were studied: lungs perfused with PSS containing the dexamethasone vehicle (control), lungs perfused with 4.2 x lo-" M dexamethasone, and lungs perfused with PSS containing the dexamethasone vehicle and 3.1 x lo-' M meclofenamate. After 1 h of perfusion the lungs were challenged twice at a lomin interval with 5 min of 0% 0,. Samples of effluent perfusate for measurement of the concentrations of prostaglandin FZry (PGF&, 6-ketoprostaglandin F1, ( 6-ketfo-PGF,,), and thromboxane B, (TxB,) by radioimmunoassay (11, 23) were collected during the fourth minute of the second hypoxic challenge. Perfusate samples for measurement of lactate and pyruvate concentrations by a lactic acid dehydrogenase method (Sigma) were collected at 5 and 55 min of perfusion. Lung weight was measured at end of perfusion and again after drying to constant weight for calculation of wet-to-dry weight ratio.
The results are presented as means t SE. They were evaluated statistically using t tests, one-way analysis of variance (ANOVA), or two-way ANOVA with repeated measurements (32). Dunnett's or Student-NewmanKeuls methods were used for simultaneous multiple comparisons. Differences were considered significant at P < 0.05. Figure 1 shows that both the in vivo and the in vitro administration of dexamethasone potentiated the pressor reactivity of PSS-perfused lungs to both hypoxia and angiotensin II. Reactivity to hypoxia was increased more dramatically than that to angiotensin II. There was a tendency for base-line (normoxic) perfusion pressure to be higher in the dexamethasone groups than in the control group at the beginning of the dose responses, and this difference was significant (P c 0.05) after completion of the response curves. Figure 2 shows that even without angiotensin II prestimulation (25), in vitro dexamethasone increased baseline perfusion pressure and potentiated hypoxic pressor reactivity in PSS-perfused lungs. The absence of hypoxic vasoconstriction in the control lungs confirms earlier reports that rat lungs perfused only with PSS show depressed hypoxic pressor reactivity (6, 24). After completion of the hypoxic dose-response curve, 0.1 pug angiotensin II caused a pressor response (ATorr) of 6.8 t 1.2 Torr in the control lungs and of 12.9 t 1.7 Torr in the lungs exposed to dexamethasone (P < 0.05). The pressor response to 5% 02 before and after the angiotensin II challenge was 0.1 t 0.03 and 0.3 t 0.24 Torr (P > 0.05) in the control lungs and 14.0 t 3.3 and 22.7 t 2.6 Torr (P < 0.05) in the dexamethasone lungs. Thus angiotensin II caused further potentiation of hypoxic vasoconstriction in the dexamethasone-treated lungs. The next experiment examined the effect of in vivo administration of dexamethasone on hypoxic and angiotensin II pressor reactivity in lungs perfused with blood collected from normal rats (Table 1) . In contrast to its dramatic effect on the poorly-reactive PSS-perfused lungs (Fig. l) , dexamethasone pretreatment of the lung donor did not cause a significant potentiation of the vigorous hypoxic pressor reactivity of blood-perfused lungs. The response curve to angiotensin II in the dexamethasone group was shifted parallel above that in the control group (Table 1) .
RESULTS
We then examined the effects on hypoxic and angiotensin II pressor reactivity of perfusion with blood collected from adrenalectomized rats and whether in vivo administration of dexamethasone to the lung donors would alter these effects (Fig. 3, Table 2 ). Whereas control lungs perfused with adrenalectomized blood were less responsive to hypoxia than were those perfused with control blood, lungs from dexamethasone-treated rats perfused with adrenalectomized blood were not (Fig. 3 ). The differences in pressor reactivity to asgiotensin II among these three groups of lungs were similar to the differences in reactivity to hypoxia (Table 2 ). There were no differences (P > 0.05) in lung wet-to-dry weight ratio among the three groups (4.4 t 0.1, 4.6 t 0.1, and 4.5 t 0.2, respectively, for controls, adrenalectomized, dexamethasone + adrenalectomized).
To test whether the effect of dexamethasone in vitro was due to stimulation of the glucocorticoid receptor, we examined whether a more physiological level of dexamethasone would also potentiate the hypoxic response and whether the potentiation was inhibited by the antiglucocorticoid progesterone. Figure 4 shows that 5 x low7 M dexamethasone potentiated hypoxic pressor reactivity in PSS-perfused lungs prestimulated with angiotensin II. The potentiation bv dexamethasone was inhibited bv 5 x lo-" M progesterone. Progesterone also reduced to some extent the hypoxic reactivity of angiotensin II prestimulated lungs not exposed to dexamethasone. -In two additional groups of PSS-perfused lungs we tested the time course of potentiation of hypoxic pressor reactivity by dexamethasone. Figure 5 shows that -40 min was required before the hypoxic pressor response of the dexamethasone-treated group began to exceed that of the control group.
The last experiment examined whether potentiation of hypoxic vasoconstriction by dexamethasone was associated with inhibition of either cyclooxygenase or glucose metabolism. Figure 6 shows that the combined in vivo and in vitro treatment with either dexamethasone or meclofenamate potentiated hypoxic pressor reactivity in PSS-perfused lungs prestimulated with angiotensin II. At the particular concentrations used, potentiation by dexamethasone was greater than that by meclofenamate. There were no differences in lung wet-to-dry weight ratio among the three groups (5.2 t 0.2, 5.1 t 0.3, and 4.7 t 0.1 for control, meclofenamate, and dexamethasone groups, respectively, n = 5 for control and dexamethasone and n = 4 for meclofenamate, P > 0.05).
The effects of in vitro treatment with either meclofenamate or dexamethasone on hypoxic vasoconstriction, perfusate levels of PGF2,, 6-keto-PGF,,,, and TxB2, and perfusate accumulation of lactate and pyruvate in PSSperfused lungs not prestimulated with angiotensin II are shown in Table 3 . Whereas both dexamethasone and meclofenamate reduced significantly the perfusate level of TxB2 and tended to reduce that of 6-keto-PGF],, dexamethasone, but not meclofenamate, potentiated hypoxic vasoconstriction. There was no significant difference in perfusate accumulation of lactate and pyruvate between dexamethasone-perfused and control lungs Lung wet-to-dry weight ratio averaged 5.4 t 0.3, 4.7 -c-0.1, and 4.8 t 0.1 (P > 0.05) for control, meclofenamate, and dexamethasone groups, respectively.
DISCUSSION
The results showed that dexamethasone either given to the lung donor before isolation or included in the perfusate potentiated hypoxic pressor reactivity in isolated, PSS-perfused rat lungs. Dexamethasone also led to small increases in base-line perfusion pressure and potentiated the pressor reactivity to angiotensin II. These findings suggest the effect of dexamethasone was associated with a general increase in vascular reactivity, rather than with a specific potentiation of hypoxic vasoconstriction. In this regard the effect of dexamethasone resembles that of excitatory substances such as plasma, angiotensin II, vanadate, 4aminopyridine, and high [K+] that increase vascular reactivity and potentiate hypoxic vasoconstriction in PSS-perfused rat lungs (24). A notable difference between the actions of dexamethasone and an excitatory substance such as angiotensin II is that whereas potentiation by the latter is essentially immediat,e (6, 24), potentiation by dexamethasone was slow in onset (see below). The addition of both dexamethasone and angiotensin II to the perfusate had an additive effect on the potentiation of hypoxic vasoconstriction.
In comparison to its marked potentiation of hypoxic vasoconstriction in PSS-perfused lungs, in vivo treatment with dexamethasone did not cause a significant increase in the already vigorous hypoxic pressor reactivity of lungs perfused with blood that was collected from intact rats and that presumably contained a high physiological level of corticosterone (30). That the vigorous hypoxic reactivity of lungs perfused with "intact" blood was due partly to an effect of corticosterone was supported by the finding of blunted hypoxic pressor reactivity in lungs perfused with blood that presumably contained a much lower level of glucocorticoid because of its collection from adrenalectomized rats (10). Furthermore, this blunted reactivity was largely reversed by the in vivo treatment with dexamethasone. Collectively, these observations support the idea that the vigorous hypoxic pressor reactivity of blood-perfused rat lungs is partly attributable to glucocorticoid activity.
It is apparent that, whereas the in vivo administration of dexamethasone led to potentiation of hypoxic vasoconstriction in the subsequently isolated lung, the endogenous glucocorticoid, i.e., the circulating corticosterone of the lung donor, did not. We do not know whether this difference was because the large in vivo dose of dexamethasone, but not the lower, physiological level of endogenous corticosterone, had induced biochemical changes in the lung that were not reversed by flushing with PSS, or because the dexamethasone, which binds more avidly than corticosterone to the glucocorticoid receptor (4), was not washed out of the isolated lung as readily as was the corticosterone.
There are four arguments for the possibility that the effects of dexamethasone were secondary to activation of glucocorticoid receptors. First, the lung of the adult rat shows a high level of glucocorticoid binding and there is nuclear localization of dexamethasone by rat lung cells (16). In the mouse lung, nuclear localization of dexamethasone occurs in alveolar type II cells, bronchiolar smooth muscle, fibroblasts, and vascular smooth muscle and endothelial cells (5). Second, whereas the in vivo dose of dexamethasone used in this study (2 mg/kg) is pharmacological, the effective in vitro concentration of 5 x 10m7 M is near the high end of the physiological range (13). Third, the potentiation of hypoxic pressor reactivity by dexamethasone was inhibited by a loo-fold higher concentration of the glucocorticoid receptor blocker, progesterone (7, 16, 28) . Furthermore, the onset of potentiation by dexamethasone was not immediate, but instead required -40 min. Although this latency period is shorter than the hours required for some biological effects of glucocorticoid activity, it is similar to others that are apparently mediated by receptor stimulation and subsequent RNA and protein synthesis (7, (12) (13) (14) . TABLE 2. Dose-response curves to angiotensin II in lungs isolated from either control or dexamethasone-treated (2 mg/kg) rats and perfused with blood collected from either control or adrenalectomized rats ---. The results of our study are opposite those of who reported that the glucocorticoid methylprednisolone (Solumedrol) inhibits hypoxic vasoconstriction in isolated, blood-perfused rat lungs. A possible explanation of the difference between the two studies is that, whereas we used 4.2 x lo-" M dexamethasone in our experiments, Stromme-Hansen et al. used 3-9 x lo-" M methylprednisolone in theirs. Because the inhibitory effect of this large pharmacological dose of methylprednisolone was essentially immediate (33), it was possibly due to some nonspecific effect rather than to stimulation of the glucocorticoid receptor (2, 3, 13).
The acute administration of glucocorticoids to various tissues and cells has numerous biochemical effects including decreased glucose metabolism (13, 28) and inhibition of phospholipase A2 activity and a resultant decreased release of arachidonic acid (8, 9, (12) (13) (14) 18 striction in isolated rat lungs, we tested whether either of these actions was involved in the potentiation of hypoxic pressor reactivity by dexamethasone.
Our measurements of perfusate lactate and pyruvate accumulation indicated that dexamethasone did not significantly depress glucose metabolism by the lung. Thus it is unlikely the dexamethasone-induced potentiation was due primarily to inhibition of glucose metabolism.
Studies with PSS-perfused guinea pig lungs indicate that glucocorticoids inhibit a relatively high basal phospholipase A2 activity and reduce the production of cyclooxygenase metabolites in response to numerous stimuli (8, 9, 14, 18) . Based on this information and the observation that PSS-perfused rat lungs generate abnormal amounts of the vasodilator prostacyclin (17), it is possible that dexamethasone-induced potentiation of hypoxic pressor reactivity was due partly to inhibition of phospholipase A2 activity and a reduced synthesis of prostacyclin and other vasodilatory metabolites of cyclooxygenase. This possibility is supported by our observations that an inhibitor of cyclooxygenase, meclofenamate, also potentiated hypoxic reactivity in PSS-perfused lungs prestimulated with angiotensin II, and that meclofenamate and dexamethasone had similar inhibitory effects on the generation of the cyclooxygenase metabolites, TxB2, PGF2,, and 6-keto-PGF,,.
It is apparent, however, that decreased generation of cyclooxygenase metabolites was not the only important action of dexamethasone.
For example, dexamethasone seemed more effective than meclofenamate in potentiating hypoxic pressor reactivity in angiotensin II prestimulated lungs, and whereas the glucocorticoid potentiated hypoxic vasoconstriction in PSS-perfused lungs not prestimulated with angiotensin II, the cyclooxygenase blocker did not.
There is evidence for (26) and against (21) important component of the mechanism of hypoxic pulmonary vasoconstriction. If acute glucocorticoid activation reduces the availability of arachidonic acid to the lipoxygenase pathway (8,9, 13), then our findings would provide further evidence against the mediation of hypoxic vasoconstriction by a lipoxygenase metabolite. It should be noted, however, that inhibition of rat lung leukotriene synthesis by dexamethasone has not been established.
Other biochemical effects of glucocorticoid treatment that might be involved in the potentiation of hypoxic pulmonary vasoconstriction include alteration of mitochondrial metabolism (1, 19, 31) , decreased generation of superoxide anion (11, 27) , inhibition of mast cell degranulation and histamine release (13, 18), increased Na+-K'-adenosine triphosphatase (ATPase) activity (19, ZO), and stimulation of a plasma membrane Na'/H' exchanger leading to intracellular alkalinization (15, 22, 2% In summary, this study indicated that glucocorticoid activity facilitated the development of hypoxic pressor reactivity in isolated rat lungs. The results support the idea that the difference in reactivity between blood-and PSS-perfused rat lungs is due partly to a higher glucocorticoid activity with blood than with PSS. However, it was also apparent that glucocorticoid was not absolutely essential to development of significant hypoxic vasoconstriction and that there are additional factors in blood that contribute to the conditions necessary for optimal hypoxic pressor reactivity in isolated lungs. In other words, glucocorticoid activity seemed to act as an optimizing or permissive cofactor, rather than as an integral component of the hypoxic mechanism. The mechanism of action of glucocorticoid stimulation was not shown, but there was evidence that it was associated with an increase in vasoreactivity, which is an important determinant of hypoxic pressor reactivity (24). A reduction of arachidonic acid metabolism in the cyclooxygenase pathway probably contributed to, but did not fully account for, the glucocorticoid effect. We do not know whether glucocorticoid activity is important to the degree of hypoxic pressor reactivity in intact rats or whether the present results in rat lungs can be extrapolated to the isolated lungs of other species.
